The Grimm lab in the Molecular Pharmacology Program focuses on the development of novel and innovative molecular imaging approaches for cancer diagnostics, predominantly based on activatable imaging agents. These approaches combine and utilize modern biology, nanotechnology, chemistry and physics with modern imaging methods (MRI, optical imaging, PET and Cerenkov) to create novel imaging agents that allow much earlier detection and improved therapy monitoring of cancer.
